Merck KGaA donates multiple sclerosis med Rebif to French COVID-19 trial
With drugmakers scouring their portfolios for possible COVID-19 therapeutics, meds approved years ago are now being viewed with fresh eyes. That's the case for Merck KGaA's aging multiple sclerosis med Rebif, which French clinicians are now hoping could help ease symptoms caused by the novel coronavirus.